Figure 2From: Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant Escherichia coli in ICU: A retrospective studyPercentages of patients infected with PIP-TAZ R isolates or with PIP-TAZ S isolates who were receiving appropriate antibiotic therapy (defined as at least 1 agent to which the infecting organism was susceptible) ≤ 24 h and ≤ 48 h after samples were obtained for culture.Back to article page